A Leading Practitioner, Teacher and Lecturer, Dr. Talaie Adds Breakthrough G4 Implants Solution Diagnosis and Aftercare Services To Her Los Angeles Practice

SAN FRANCISCO, CA / ACCESSWIRE / April 25, 2019 / Dr. Maryam Talaie, a leading dental practitioner based in Los Angeles, has become the newest prominent dentist to join the fast-growing G4 by Golpa Dental implants Solution national affiliates network.

Dr. Talaie has devoted her more than 20-year career to educating and treating her patients with gentle and minimally invasive dental care. A graduate of the University of Southern California, Dr. Talaie is recognized in the field of dental sciences where she remains current with the latest technology and research on the safest dental methods and materials available.

The G4 by Golpa Implants Solution Affiliates Network provides consumers with access to the exclusive G4 Precision Implant Dentistry, perfected by renowned dentist Dr. Mike Golpa (www.g4bygolpa.com) after years – and over 6,000 dental implant surgeries. G4 network dental affiliates receive advanced training by Dr. Golpa in the diagnosis and aftercare of the G4 Implant Solution. Patients have the convenience of accessing a local dentist within the G4 affiliates network to arrange for the exclusive G4 dental implant procedure and receive comprehensive after-treatment care.

Dentists within the G4 by Golpa Affiliates Network are fully trained by Dr. Golpa to provide follow-up care with patients after they undergo the surgical procedure, which is conducted at the G4 surgical centers located in Las Vegas, Dallas and Virginia. The G4 Affiliate Program empowers dentists to add a state-of-the-art dental implant program without having to incur any capital investment.

“Dr. Golpa has developed a truly state-of-the-art, superior procedure in the ever-growing area of dental implants. As a dentist interested in expanding into implants, I am excited to become part of the G4 network and bring this remarkable implant solution to patients throughout Northern California,” said Dr. Talaie.

“We are extremely pleased to welcome Dr. Maryam Talaie to the G4 Implants Solution affiliates network. Dr. Talaie is a passionate advocate for best practices in dental care and is highly regarded by patients for his steadfast commitment to proactive dental hygiene, self-care and maintenance. An organization is best defined by the company it keeps – and having Dr. Talaie as a member of G4 underscores the innovativeness and effectiveness of our Implants Solution,” said Dr. Golpa.

About the G4 by Golpa Implant Solution Affiliates Network:

Dr. Mike Golpa’s G4 Implant Solution is practiced in regions across the US by top dentists fully trained in the G4 implant procedure. Dr. Golpa’s G4 Implants Solution has ‘broken the mold’ in providing advanced dental implants technologies, introducing a treatment that delivers a permanent bridge with titanium framework in just one visit. The G4 Implants procedure encompasses proprietary all-digital protocols and next generation milling technologies developed by Dr. Golpa that are changing the cosmetic dentistry landscape. In addition to the continuing expansion of G4 Implant Solutions surgery centers and growing number of dentists adopting the G4 technology, the popularity and proven effectiveness of Dr. Golpa’s procedure has resulted in the government’s approval to offer Medicare support for G4 dental implant patients.

CONTACT:

Steve Syatt
SSA Public Relations
Steve@ssapr.com
(818) 222-4000

SOURCE: Dr. Mike Golpa

ReleaseID: 543051

SANTA MONICA, CA / ACCESSWIRE / April 25, 2019 / Parallax Health Sciences, Inc. (OTCQB: PRLX) (”Parallax” or the ”Company”), an outcome-driven connected healthcare company, announces that management will present at the Planet MicroCap Showcase on Wednesday, May 1, 2019 at 4:30 p.m. Pacific time and conduct individual investors meetings on Thursday, May 2, 2019.

The conference will be held April 30-May 2, 2019 at Bally’s Hotel & Casino in Las Vegas. For those interested in meeting with management, please contact Robert Kraft at rkraft@snnwire.com or (424) 227-9018, or visit www.planetmicrocapshowcase.com for more information.

About Parallax Health Sciences

Parallax Health Sciences is an advanced technology, outcome-driven telehealth company that allows for cost-effective remote diagnosis, treatment and monitoring of patients through proprietary platforms of integrated products and services. The Company’s interoperable novel applications provide patients point-of-care testing and monitoring with information communicated via internet-based mobile phone applications that are agnostic as to operating system and are built on highly sophisticated data analytics. Information is retrieved real-time by physicians who are monitoring patients with chronic diseases or through biometric feedback for health-related behavior modification, and is automated for integration into electronic health records. The Company’s products and offerings capitalize on the digital transformation in healthcare for improved patient compliance, diagnosis and treatment, and support healthcare system cost savings and efficiencies. For more information, please visit www.parallaxcare.com.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our Form 10-K and other reports filed with the SEC. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100

SOURCE: Parallax Health Sciences, Inc.

ReleaseID: 543031

Search for Gems, See Baby Wildlife, Bag a Peak or Road Trip in Nevada

CARSON CITY, NV / ACCESSWIRE / April 25, 2019 / Rockhounds, nature-lovers and adventure-seekers have their fun cut out for them this spring in the Silver State. Rounding out the recreation: a tasty food and beverage scene and a calendar full of festivals. All you need for spring in Nevada is a map, a buddy and a knockout playlist for your road trip. Here, TravelNevada offers suggestions for an epic experience.

Hunt for gold and garnets – Nevada is known as the Silver State because of its prolific silver mines of the late 19
th and early 20th centuries. These days, the state is a major gold producer – Nevada mines generated 5.6 million ounces of gold in 2017, according to the Nevada Division of Minerals – with much of the mining activity in the Elko/northern Nevada area. For information on mine tours, visit the Elko Convention and Visitors Authority web page here. For more hidden gems, head to Garnet Hill outside of Ely. At this federally managed rockhounding site, hunt for garnets in the area’s volcanic outcroppings. For more information, visit the Bureau of Land Management’s Garnet Hill page here.

Spot a baby animal – Nevada has vast swaths of public land: beautiful landscapes supporting various mammal and bird species. Spot gangly spring ponies in the Carson Valley, Bighorn lambs roaming Valley of Fire, or find baby burros throughout the Black Rock Desert. Birders may want to visit the Stillwater National Wildlife Refuge near Fallon, where over 300 species of birds can be found across 79,000 acres of marshes and desert landscapes.

Hike the Nevada Big Five – With 320 named mountain ranges, more than 172 summits and eight ultra-prominent peaks, Nevada is the most mountainous state in the lower 48. With sunny days and mild temperatures, the state’s five tallest peaks are well worth the climb. Hit the road this spring to discover them all.

Mount Charleston, 11,916′ (part of the Spring Mountains
National Recreation Area)
Mount Jefferson, 11949′ (part of the Alta Toquima Wilderness in central Nevada)
Mount Moriah, 12,073′ (part of the Mount Moriah Wilderness north of Ely)
Wheeler Peak, 13,064′ (inside Great Basin National Park in Baker)
Boundary Peak, 13,147′ (inside
Boundary
Peak Wilderness near Dyer)

Cin Cin! Treat yourself to Italian cuisine and farm-to-flask distilleries – Eataly Las Vegas has opened a new location in Las Vegas at the Park MGM. The gastronomic marketplace brings Italian culture to southern Nevada with 40,000 square feet of cafes, bars, chef’s counters, markets and restaurants. Inspired by the motto “anything is possible,” Eataly Las Vegas is open 24 hours and features cooking classes, wine on tap, street food from Rome, three pizza kitchens, fresh pasta and a Nutella bar. In northern Nevada, the newly opened Bently Heritage Estate Distillery in Minden embraces a farm-to-flask culture, with liquor made from grains grown on the nearby Bently Ranch. The distillery is one of four estate distilleries in the country and occupies the 100-year-old Minden flour mill.

Spring Road Trip: The Lake Tahoe Loop. Nevada is 110,572 square miles – the seventh largest state in the Union. It is made for road tripping, and TravelNevada has developed 10 signature road trips that take travelers from mountains to deserts, through ghost towns and on byways. Drive the Lake Tahoe Loop this spring, starting in the hip, eclectic and growing city of Reno. Enjoy the burgeoning Midtown and Riverwalk districts, with boutique shopping, craft beer, farm-to-table restaurants and a Burning Man-inspired art scene. Then head to North Lake Tahoe for some alpine adventure and mountain culture. Rediscover the glamour of the 1950s at the Tahoe Biltmore or the Crystal Bay Casino – two historical lakefront properties. In Stateline, enjoy a round of golf at Edgewood Tahoe – the golf resort’s newly opened Lodge at Edgewood Tahoe was named No. 1 Resort Hotel in the U.S. by Travel + Leisure in 2018. Explore the past at the Genoa Bar in Genoa; which dates back to 1853 and claims to be “Nevada’s oldest thirst parlor,” or check out the Transcontinental Railroad Exhibit commemorating the 150th anniversary of the Transcontinental Railroad at the Nevada State Railroad Museum in Carson City.

Celebrate spring, Nevada-style. Embrace Nevada’s unique and quirky festivals, dirt bike races through haunted ghost towns and Dutch oven cooking. See below for a list of upcoming events.

Genoa Western Heritage Days, April
26-28. Nevada’s oldest settlement celebrates its history with cowboy poetry, American Indian demonstrations, live music and Dutch oven cooking.

Virginia City Grand Prix, April
27-28. Dirt bikers race through the mountains, old mining roads and the historic and haunted Virginia City.

Wild West Extravaganza, May
3-5. A youth rodeo, outhouse races, trail rides and more are scheduled for this event celebrating southern Nevada’s Wild West heritage in Pahrump.

Reno River Festival, May
11-12. Music, craft beer vendors, and an adventure park with rides are part of the fun at this event in downtown Reno.

About TravelNevada The Nevada Division of Tourism (TravelNevada) is part of the Nevada Department of Tourism and Cultural Affairs. It promotes and markets Nevada as a tourism destination for domestic and international leisure and business travelers through its marketing and advertising programs and by coordinating partnerships between public and private entities. TravelNevada also administers grant programs for local entities to market travel and tourism offerings and publishes Nevada Magazine.

EDITORS: Download high-resolution photos here.

Contact:

Bethany
Drysdale, bdrysdale@travelnevada.com
Chris Moran, cmoran@travelnevada.com
Nevada Division of Tourism, 775 687 0647
TravelNevada.com

SOURCE: TravelNevada

ReleaseID: 543030

Company’s intelligent perception technology for industrial robots is revolutionizing global industries

WATCH A VIDEO OF PLUS ONE’S TECHNOLOGY

SAN ANTONIO, TX / ACCESSWIRE / April 25, 2019 / Plus One Robotics, a leader in developing artificial intelligence and sensor technology that allows industrial robots to learn and adapt in fast-paced dynamic environments, is growing.

As worldwide demand for its technology increases, the San Antonio-based firm is more than doubling its research, prototyping and administrative operations from 4,000 to more than 10,000 square feet at Port San Antonio-the large technology campus just southwest of the city’s downtown. The company will also expand its workforce to more than 30 employees, including engineers and business development personnel, to pursue a range of opportunities.

Based at the Port since 2018, Plus One develops 3D-vision and artificial intelligence (AI) robotics software used by industrial, logistics and e-commerce operations around the world. Through this innovative technology, clients can shift employees into greater value-added roles as robots are increasingly used to complete monotonous tasks such as package sorting, induction or each-picking.

Plus One’s technology can be integrated into any brand of existing industrial robots. Unlike traditional robots that can only accomplish a limited range of pre-programmed tasks, units outfitted with Plus One’s suite can adapt to changing industrial environments and adjust to situations such as surges in volume and packages of variable types and sizes in large logistics operations.

Other industries targeted by the company include manufacturing, aerospace and automotive. “Every major manufacturing operation in the country has a large flow of materials through their facility. Our products help them optimize the handling of those processes,” says company co-founder Erik Nieves.

“We see a true world of opportunities for the application of these innovations,” he added. “With increased global demand for the production and delivery of goods, there is a bright future ahead for technologies that make those processes more efficient-assuming repetitive functions and allowing people to transition to more engaging and sophisticated work, including the continuous improvement of the systems we’re developing.”

“What Plus One Robotics is doing epitomizes what we are building at Port San Antonio: a place that brings together talent and improves our key industries,” says Port President and CEO Jim Perschbach. “The fact that Plus One Robotics is working to creatively integrate logistics, robotics, software and cybersecurity technologies serves as an inspiring example for current and future innovators in our community. We’re excited about the opportunities these tech pioneers have ahead of them.”

Plus One’s groundbreaking technology has garnered significant attention from industries that rely on robotics as well as the investment community. The company secured $8.3 million second round funding led by Pritzker Group Venture Capital and Zebra Technologies in the fall of 2018. That investment was in addition to Plus One Robotics’ first round of funding in the amount of $2.4 million.

Media Contacts:

Paco Felici paco.felici@portsanantonio.us / (210) 260-3218
Stephanie Garcia stephanie.garcia@portsanantonio.us / (210) 238-8657

SOURCE: Port San Antonio

ReleaseID: 543022

SANTIAGO, CHILE / ACCESSWIRE / April 25, 2019 / Coca-Cola Andina announced today that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2018 with the U.S. Securities and Exchange Commission. The document can be accessed by visiting either www.koandina.com or www.sec.gov.

Shareholders may receive a hard copy of the report, which includes Coca-Cola Andina´s audited financial statements, free of charge through the contact listed above.

Coca-Cola Andina anunció hoy que el documento 20-F para el ejercicio terminado el 31 de diciembre de 2018 fue presentado ante la Comisión de Valores e Intercambios de los EE.UU. El documento se encuentra disponible en inglés a través de www.koandina.com o www.sec.gov.

Los accionistas podrán recibir una copia impresa gratuita del informe, el cual incluye los estados financieros auditados de la sociedad a través del contacto señalado en la parte superior de este documento.

Contact / Contacto en Santiago, Chile

Ignacio Morales, Finance and Treasury Manager / Gerente de Finanzas y Tesorería

(562) 2338-0520 / andina.ir@koandina.com

SOURCE: Coca-Cola Andina

ReleaseID: 542917

NEW YORK, NY / ACCESSWIRE / April 25, 2019 / Gaucho Group Holdings, Inc. (OTCQB: VINO), a company with a collection of luxury assets, real estate holdings and premium wines in Argentina, today announced that they have reached an agreement with Compass Real Estate, in conjunction with Argentine Real Estate firm Ginevra Sotheby’s International Realty, to market and sell home sites at Algodon Wine Estates, a 4,138 acre luxury real estate development with over 400 estate lots for sale in San Rafael, Mendoza, Argentina.

Compass Real Estate (www.compass.com), dubbed “the country’s fastest-growing luxury real estate technology brokerage company” by Forbes Magazine, is set to revamp Algodon Wine Estates’ marketing and global sales initiatives by utilizing its network of 7,000 agents and over 1,000 employees. Compass’ business model has attracted investment capital from Fidelity, Softbank, Goldman Sachs, and several other corporations and individuals.

In addition to this, Algodon Wine Estates intends to leverage Ginevra Sotheby’s International Realty brand and network with more than 18,000 sales associates located in 825 offices in 61 countries and territories worldwide, while utilizing the local expertise of the GNV Group to form Ginevra Sotheby’s International Realty. Ginevra Sotheby’s International Realty is a leading luxury real estate firm in Buenos Aires, Argentina with listings in the most prestigious neighborhoods in the city of Buenos Aires and the rest of the country. Through Ginevra Sotheby’s International Realty’s website (ginevrasir.com), and Compass, Algodon Wine Estates’ listings will be marketed online at sothebysrealty.com to a global clientele.

“As you know, we have embarked upon a journey to make Algodon the finest wine, wellness, culinary, and sport destination – not only in Argentina – but in in the world,” said Scott Mathis Chairman and CEO of Gaucho Group Holdings, Inc. “This has culminated in us partnering with Compass, one of the fastest growing and most technologically adept real estate firms in the world. Compass, with the assistance of local Buenos Aires Real Estate agency Ginevra Sotheby’s International Realty, is set to launch a major marketing push in the next quarter that could possibly reach millions of potential buyers.” He went on to say, “the road in Argentina has not been the smoothest over the past few years, but now we believe the timing could not be better… with an impending election in October, on a re-election of incumbent President Mauricio Macri, we anticipate a positive paradigm shift, attracting international interest in the Argentine economy, and in turn domestic real estate assets. It is because of this potential shift that we believe Argentina can become the global opportunity of the next decade.”

Please visit www.algodonwineestates.com to learn more about this real estate development project.

About Algodon Wine Estates

Algodon Wine Estates is a 4,138 acre (1674 ha) world-class wine, wellness, culinary and sport resort, and luxury real estate development, located in the rolling hills of the Sierra Pintada Mountains in San Rafael, Mendoza, Argentina. This wine and golf community is a global destination that includes approximately 400 lots ranging from .5 to 7 acres, with 109 lots from Phase 1 of the master plan currently available for private sale and development. Surrounded by the natural beauty of vineyards, fruit orchards and olive groves, many lots have pre-existing vines and groves, and a significant number of available Phase 1 lots are situated directly on the estate’s 18-hole golf course, offering golf, vineyard and mountain views. The luxury destination is truly unique in the world, where residents can step right outside their front door onto the golf course and find themselves among meticulously manicured vines planted in the 1940s.

About Gaucho Group Holdings, Inc.

For more than ten years, Gaucho Group Holdings’ (formerly Algodon Group) mission has been to source and develop opportunities in Argentina’s undervalued luxury real estate and consumer marketplace. With our proprietary collection of wine, hospitality, fashion brands, and real estate holdings as a foundation, we seek to build our luxury brands of Gaucho – Buenos Aires and ALGODON, brands of prestige, distinction and elegance. We begin with a focus on the quality and reputation of Algodon’s award-wining wines, which serve as our ambassador for our luxury lifestyle properties and other real estate assets. As we continue to produce the ultra-fine wines for which we have become recognized, we expect that our reputation for quality will continue to grow and accordingly increase the value of our brand and real estate holdings. Algodon’s luxury assets are currently concentrated in Argentina, which we believe represents one of the most undervalued investment sectors in the world today. For more information, please visit www.gauchogroupholdings.com.

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this press release includes “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). All statements, other than statements of historical facts, included herein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. These forward-looking statements are identified by their use of terms and phrases such as “may,” “expect,” “estimate,” “project,” “plan,” “believe,” “intend,” “achievable,” “anticipate,” ” will,” “continue,” “potential,” “should,” “could,” and similar terms and phrases. Although we believe that the expectations reflected in these forward-looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not be considered to be) guarantees of future performance. Among these risks are those set forth in a Form 10-K filed on April 1, 2019. It is important that each person reviewing this release understand the significant risks attendant to the operations of Gaucho Group Holdings. Gaucho Group Holdings disclaims any obligation to update any forward-looking statement made herein.

CONTACT:

Media and Investor Relations:
Gaucho Group Holdings, INC.
Rick Stear
Director of Marketing
212.739.7669
rstear@algodongroup.com

SOURCE: Gaucho Group Holdings, Inc.

ReleaseID: 543025

PHILADELPHIA, PA / ACCESSWIRE / April 25, 2019 / The world’s first global blockchain mission with the sole purpose of protecting of the tropical rainforests around the world, PURELAND Earth, has been launched in Latin America with PURELAND Zero.

Tropical rainforests are the primary absorbers of large amounts of carbon dioxide produced by humans, livestock and man-made facilities. Today, rainforests are under unprecedented threat of deforestation as the world is facing the largest climate crisis in the history of mankind. Rainforests cover only two percent of the total surface area of the planet, yet are home to nearly half of all known plant and animal life.

The PURELAND Zero emission removal project has the objective to preserve the existing primeval rainforest cover on an area of 841.7 hectares in the Térraba Sierpe Forest Lands.

The Térraba Sierpe Forest Lands are among the largest mangrove forest wetlands in all of Central America. They are a unique and fragile ecosystem, located in Costanera Sur on the Osa peninsula in Puntarenas province in Costa Rica.

The Térraba Sierpe are home to seven species of mangrove including crawler red mangrove and also inhabited by many species of animals, mammals such as white face monkey, marmoset, raccoon, and sloths, as well as numerous species of reptiles, birds and aquatic life.

Supporters of PURELAND Zero are helping to preserve rainforest and riverine wetland for future generations. Rainforest land that has been protected with PURELAND Zero can no longer fall prey to large corporations responsible for rainforest deforestation and environmental devastation.

For maximum safety, donations generate encrypted digital certificates of land protection on the blockchain. All contributions made to the PURELAND project are utilized for monitoring ongoing projects and financing further environmental projects to save the planet.

The PURELAND
Foundation was founded by a group of innovators in the fintech industry who want to make a global societal difference, to combat climate change and to protect the environment. The Foundation supports the creation of positive-impact long-term investment for environmental sustainability and protection.

Visit info.pureland.earth to donate.

DONATION – PURELAND – pureland.earth: https://info.pureland.earth/

PURELAND (@purelandearth) – Twitter: https://twitter.com/purelandearth

PURELAND – Facebook: https://www.facebook.com/pureland.earth

Contact
Information:

PURELAND Foundation Inc.

123 South Broad Street, Suite 1640

Philadelphia, PA 19109
support@pureland.earth

SOURCE: PURELAND Foundation Inc.

ReleaseID: 543012

Efficacy data from the REIMAGINE Phase IIa basket trial’s Attention Deficit Hyperactivity Disorder (ADHD) cohort
Second positive report of vafidemstat in a human CNS indication
Company announces decision to pursue further development of vafidemstat in psychiatric indications

MADRID, SPAIN and CAMBRIDGE, MA / ACCESSWIRE / April 25, 2019 / Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces that the company will be presenting additional human efficacy data with its CNS epigenetic drug vafidemstat. Specifically, Oryzon will present data from its Phase IIa clinical trial REIMAGINE at the 7th World Congress on ADHD that will be held from Apr 25 – 28 at the Lisbon Congress Center, Lisbon, Portugal.

The preliminary REIMAGINE results to be presented include data from the ADHD cohort as well as aggregated data for the ADHD and Borderline Personality Disorder (BPD) cohorts.

A communication in the form of a Poster entitled “Vafidemstat is safe and effective in treating adult ADHD patients: Phase II REIMAGINE clinical trial” will be presented by Oryzon’s Medical Director, Dr. Roger Bullock, on April 27th 12:45 – 14:15 during the Session P20 Pharmacological treatment I at Pavilion 5.

Vafidemstat met the primary endpoint, as it was safe and well tolerated without significant adverse events.

In terms of efficacy, after 2 months of vafidemstat treatment statistically significant findings included:

In the ADHD patients, global improvement on the Clinical Global Impression (CGI) Severity (CGI-S) and CGI-Improvement (CGI-I) scales was significant (p=0.0043 and p=0.0352, respectively).

When considered the aggregated data from ADHD and BPD patients, global improvement on the CGI-S and CGI-I scales exhibited higher statistical significance (p<0.0001 and p=0.0015, respectively) than the ADHD and BPD cohorts alone.

In the ADHD patients, global improvement on the Neuropsychiatric Inventory (NPI) total score was significant (p=0.0016). Specific improvement on the NPI 4-item Agitation/Aggression subscale was also significant (p=0.0043).

When considered the aggregated data from ADHD and BPD patients, global improvement on the Neuropsychiatric Inventory (NPI) total score and NPI 4-item Agitation/Aggression subscale exhibited higher statistical significance (p=0.0006 and p<0.0001, respectively) than the ADHD and BPD cohorts alone.

A significant overall improvement in the ADHD Rating Scale (ADHD-RS) total score was also observed (p=0.0279).

In summary, vafidemstat produced significant improvements in ADHD patients across several commonly used scales that measure agitation and aggression. In addition, the significant improvements in the Total NPI score and overall ADHD-RS score suggest that vafidemstat has a broader psychiatric effect beyond agitation and aggression. Likewise, aggregated data from the ADHD and BPD combined cohorts doubled the sample size and significantly improved scores on agitation/aggression.

Dr. Carlos Buesa, CEO of the company, stated: “These results are confirming the previous findings in BPD patients reported recently at EPA2019 and highlight the potential of vafidemstat to be developed in a broad range of psychiatric indications. The company considers that vafidemstat is providing a differential therapeutic proposition on these conditions: some, as BPD, with no current approved treatments, and some others, like ADHD, where current treatments have unfavourable side effect profiles. Oryzon will pursue the development of vafidemstat in psychiatric indications. The company has started a dialogue with KOLs to assess what would likely be required to achieve clinical success and market approval”.

For more information on this event please visit https://www.adhd-congress.org/

For a complete view of the poster please visit https://www.oryzon.com/sites/default/files/20190425 ORYZON_ADHD_poster.pdf

REIMAGINE (EudraCT Number 2018-002140-88) is a Phase IIa ‘basket’ clinical trial to evaluate the safety, tolerability and efficacy of vafidemstat in aggression in adult population with CNS disorders, including three psychiatric disorders (BPD, ADHD and Autism Spectrum Syndrome (ASD)). This trial includes 6 patients per indication and is being conducted in Spain at the Vall d’Hebrón hospital in Barcelona. REIMAGINE is designed as a single-arm, open-label, 8-weeks treatment study.

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds vafidemstat and iadademstat in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon has offices in Spain and the United States. For more information, visit www.oryzon.com

About Attention Deficit Hyperactivity disorder

ADHD is a neural development disorder characterized by a persistent pattern of difficulty paying attention, hyperactivity, and impulsive behavior. It is considered to be a chronic disorder that commences in infancy and persists into adult age in more than 50% of cases. Adult ADHD has a prevalence about 2.5-4% of the general adult population. ADHD is associated in adults as well as children with a general pattern of problems in academic performance and social, family and work-related adaptation, giving rise to high economic and healthcare costs.

About Borderline Personality Disorder

BPD is the most frequent personality disorder. It is estimated that its prevalence ranges from 0.5% to 1.4% in the general population, between 11% and 20% in outpatients, between 18% and 32% in patients hospitalized in psychiatric units and between 25% and 50% in prison inmates. BPD is one of the most complex, functionally debilitating and costly psychiatric conditions currently facing the mental health systems. Patients with BPD typically experience emotional instability, impulsivity, irrational beliefs and distorted perception, as well as intense but unstable relationships with others. Up to 10% of people affected die by suicide. Women are diagnosed about three times as often as men. It is a significant unmet medical need. There are currently no approved drugs by the FDA to specifically treat BPD.

About Vafidemstat

Vafidemstat (ORY-2001) is an oral, brain penetrant drug that selectively inhibits LSD1 and MAOB. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same time has neuroprotective effects. In animal studies vafidemstat not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice, a model for accelerated aging and Alzheimer’s disease, to normal levels and also reduces social avoidance and enhances sociability in murine models. In addition, vafidemstat exhibits fast, strong and durable efficacy in several preclinical models of multiple sclerosis (MS). Vafidemstat is in Phase IIa clinical studies in patients with Relapse-Remitting and Secondary Progressive MS (SATEEN), in patients with Mild to Moderate Alzheimer’s disease (ETHERAL) and in aggressiveness in patients with different psychiatric or neurodegenerative disorders (REIMAGINE, a basket trial).

FORWARD-LOOKING STATEMENTS

This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzon’s securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzon’s securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.

CONTACT:

US Contact:
Solebury Trout
Thomas Hoffmann
+1 646 378 2932
thoffmann@troutgroup.com

Spain:
ATREVIA
Patricia Cobo/Idoia Revuelta
+34 91 564 07 25
pcobo@atrevia.com
irevuelta@atrevia.com

Oryzon:
Emily Torrell
BD Director
+34 93 515 13 13
etorrell@oryzon.com

SOURCE: Oryzon Genomics, S.A.

ReleaseID: 543021